TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16272867

Group type: EXPERIMENTAL
Intervention: Patients with Wilson disease
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients with Parkinson disease
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patients with multiple sclerosis
Number of subjects: 47
Study: 12228773

Group type: EXPERIMENTAL
Intervention: Carvedilol administered twice daily for 8 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 150
Study: 10212732

Group type: EXPERIMENTAL
Intervention: PACST test consisting of 60 Yes-No questions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal performance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impaired performance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chance performance group
Number of subjects: 0
Study: 8560136

Group type: EXPERIMENTAL
Intervention: Actigraphic assessment method for periodic leg movements (PLM)
Number of subjects: 30
Study: 2151874

Group type: EXPERIMENTAL
Intervention: Fentanyl (125 micrograms/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sufentanil (25 micrograms/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both fentanyl and sufentanil
Number of subjects: 24
Study: 322671

Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam (2 mg orally) administered for 7 consecutive evenings
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for 2 days
Number of subjects: 33
Study: 29352401

Group type: EXPERIMENTAL
Intervention: Choice condition (offered choice of intervention from PMTO formats or services-as-usual)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon Model (PMTO)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Services-as-usual (SAU) within the no-choice condition
Number of subjects: 129

Group type: COMPARATOR
Intervention: No-choice condition (randomized to one of the four intervention conditions)
Number of subjects: 129
Study: 28917235

Group type: EXPERIMENTAL
Intervention: new amino acid-based formula (nAAF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: commercial amino acid-based formula (cAAF)
Number of subjects: 36
Study: 25520045

Group type: EXPERIMENTAL
Intervention: Presentation of label options prior to smelling (normosmic subjects)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Presentation of label options after smelling (normosmic subjects)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Verbal descriptors only (both groups)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Verbal descriptors and pictures (both groups)
Number of subjects: 200
Study: 22735897

Group type: EXPERIMENTAL
Intervention: Multimodal Anxiety and Social Skills Intervention (MASSI) program
Number of subjects: 30
Study: 21688560

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 177

Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AIN's)
Number of subjects: 177
Study: 19214594

Group type: EXPERIMENTAL
Intervention: Yoga of Awareness program (gentle yoga poses, meditation, and breathing exercises)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Yoga of Awareness program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 37
Study: 16766370

Group type: EXPERIMENTAL
Intervention: Subacromial decompression
Number of subjects: 90

Group type: COMPARATOR
Intervention: Graded physiotherapy and exercises
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-reported outcomes after 4-8 years
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Changes in indices after 4 years
Number of subjects: 90
Study: 12720065

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 20
Study: 10698481

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 22
Study: 9119980

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1000 mg daily for 3 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral methylprednisolone 48 mg daily for one week, 24 mg daily for one week, and 12 mg daily for one week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral methylprednisolone regimen
Number of subjects: 22
Study: 8222034

Group type: COMPARATOR
Intervention: Sitting position with 2.0 ml hyperbaric bupivacaine 0.5%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Left lateral position with 2.0 ml hyperbaric bupivacaine 0.5%
Number of subjects: 50
Study: 3531044

Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) approximately 2 mg per kilogram body weight per day for 21 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not receiving the drug)
Number of subjects: 50
Study: 31132088

Group type: EXPERIMENTAL
Intervention: Videoconference-adapted GLB program
Number of subjects: 43

Group type: COMPARATOR
Intervention: In-person GLB program
Number of subjects: 43
Study: 30095769

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 130

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 130
Study: 27779460

Group type: EXPERIMENTAL
Intervention: Lercanidipine + Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine + Enalapril
Number of subjects: 0
Study: 25490803

Group type: EXPERIMENTAL
Intervention: Self-leveling pallet carousel
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Adjustable cart
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combination of self-leveling carousel and adjustable cart
Number of subjects: 13

Group type: COMPARATOR
Intervention: Traditional palletizing conditions
Number of subjects: 13
Study: 22468424

Group type: EXPERIMENTAL
Intervention: Affect-improving interpersonal affect regulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect-worsening interpersonal affect regulation
Number of subjects: 0
Study: 20224931

Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3) for 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Washout period after probiotic
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline (pre-probiotic)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3) for 4 weeks in high oxalate absorbers
Number of subjects: 11
Study: 18565465

Group type: EXPERIMENTAL
Intervention: Educational intervention promoting awareness of satiety cues and discouraging bottles containing more than 6 ounces before 4 months of age.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group received education regarding introduction and feeding of solid food after 4 months of age.
Number of subjects: 104
Study: 15973772

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 51
Study: 12047603

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 mg brotizolam (BR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inactive placebo (PL)
Number of subjects: 10
Study: 10399200

Group type: EXPERIMENTAL
Intervention: AIDS prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal measures
Number of subjects: 0
Study: 7546753

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia with plain 1% lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with general anesthesia
Number of subjects: 20
Study: 2265259

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TM), 30 mg per day for 2 years
Number of subjects: 308

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 308
Study: 7417366

Group type: EXPERIMENTAL
Intervention: Ticlopidine (5‐(6‐chlorobenzyl)‐4,5,6,7‐tetrahydrothieno‐(3,2‐C)‐pyridine HCl) for one or four months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 12
Study: 31426760

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) with doses of 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, completed within 2 weeks.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard of care palliative-intent treatments (Control group).
Number of subjects: 159
Study: 28351963

Group type: EXPERIMENTAL
Intervention: 24-hour ischemic lesion volume (ILV) measured by noncontrast computed tomography
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 1-week ischemic lesion volume (ILV) measured by noncontrast computed tomography
Number of subjects: 228
Study: 25862428

Group type: EXPERIMENTAL
Intervention: Low-volume polyethylene glycol containing ascorbic acid (n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2 L of polyethylene glycol plus bisacodyl (n = 31)
Number of subjects: 62
Study: 24219197

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (H-PRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-intensity nonprogressive resistance training (L-RT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care control group (unsupervised walking)
Number of subjects: 22
Study: 21378213

Group type: EXPERIMENTAL
Intervention: Latinos en Control intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study: 19627261

Group type: EXPERIMENTAL
Intervention: Night-time postural equipment (NTPE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sleeping unsupported
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Study group (children with severe CP)
Number of subjects: 10
Study: 17276533

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the left breast
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Anterior internal mammary node (IMC) RT
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Anterior left breast boost RT
Number of subjects: 6680
Study: 15067425

Group type: EXPERIMENTAL
Intervention: Tagged MRI
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard bright-blood cine MRI
Number of subjects: 28
Study: 11698604

Group type: EXPERIMENTAL
Intervention: Deaf signers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hearing controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hearing native signers
Number of subjects: 0
Study: 8975918

Group type: EXPERIMENTAL
Intervention: 5-valent CRM-OS (10 micrograms of oligosaccharide per serotype)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PS) (25 micrograms of polysaccharide per serotype)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CRM-OS followed by revaccination with PS at 2 months
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CRM-OS
Number of subjects: 99

Group type: COMPARATOR
Intervention: PS
Number of subjects: 99
Study: 7932517

Group type: EXPERIMENTAL
Intervention: Pravastatin 10-40 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3370923

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at short length
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eccentric contractions at long length
Number of subjects: 8
Study: 29899643

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Intravitreal Bevacizumab with Triamcinolone (IVB/IVTA)
Number of subjects: 136
Study: 26950808

Group type: EXPERIMENTAL
Intervention: 3Mixtatin
Number of subjects: 65

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 65
Study: 25422235

Group type: EXPERIMENTAL
Intervention: Chongcao Yigan Capsule
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lamivudine (Control)
Number of subjects: 136
Study: 22178506

Group type: EXPERIMENTAL
Intervention: CPR Anytime™ self-learning kit (Rx for CPR kit)
Number of subjects: 162

Group type: COMPARATOR
Intervention: CPR class (Rx for CPR class)
Number of subjects: 162
Study: 19884368

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 25 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 50 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 125 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 1000 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 1500 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18804239

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling surgery
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655

Group type: COMPARATOR
Intervention: Preoperative urodynamic studies
Number of subjects: 655

Group type: COMPARATOR
Intervention: Maximum flow during noninvasive flowmetry
Number of subjects: 655

Group type: COMPARATOR
Intervention: Voiding pressures and degree of abdominal straining
Number of subjects: 655
Study: 15660184

Group type: EXPERIMENTAL
Intervention: Paula method of circular muscle training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pelvic floor training
Number of subjects: 59
Study: 12094846

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg and 20 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 10592838

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 7724891

Group type: COMPARATOR
Intervention: Morphine 2.5 mg i.v. on‐demand (Group 1)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Clonixin 400 mg/day i.v. infusion (Group 2)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Morphine 0.4 mg/kg/day i.v. infusion (Group 3)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Clonixin 400 mg/day plus morphine 0.4 mg/kg/day i.v. infusion (Group 4)
Number of subjects: 85
Study: 1701005

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Conventional intermittent mechanical ventilation (IMV)
Number of subjects: 673
Study: 6772386

Group type: EXPERIMENTAL
Intervention: Diltiazem, 240 mg daily dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting vasodilators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-adrenergic blockade
Number of subjects: 0
Study: 31490566

Group type: EXPERIMENTAL
Intervention: Smartphone-based patient support tool
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group without the patient support tool
Number of subjects: 664
Study: 28076921

Group type: EXPERIMENTAL
Intervention: GWWFV with taste testing
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: FFVSP
Number of subjects: 747

Group type: COMPARATOR
Intervention: GWWFV without taste testing
Number of subjects: 747

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 747
Study: 27530339

Group type: EXPERIMENTAL
Intervention: 40 ml of autologous bone marrow cells (BMCs) by local intramuscular application (n=32)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 40 ml of autologous bone marrow cells (BMCs) by intra-arterial application (n=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 62
Study: 24383962

Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin (300/120 mg combination)
Number of subjects: 9

Group type: COMPARATOR
Intervention: volume‐matched placebo
Number of subjects: 9
Study: 22257664

Group type: EXPERIMENTAL
Intervention: Infiltration: ICON‐pre‐product; DMG
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sealing: Prime‐Bond‐NT; Dentsply
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19686874

Group type: EXPERIMENTAL
Intervention: Depression diagnosed by GPs
Number of subjects: 1751

Group type: EXPERIMENTAL
Intervention: Comorbidity of somatoform, depressive, and anxiety disorders
Number of subjects: 1751

Group type: EXPERIMENTAL
Intervention: Somatoform/functional disorder only
Number of subjects: 1751
Study: 17710839

Group type: EXPERIMENTAL
Intervention: Migraid device
Number of subjects: 134

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 134
Study: 15447697

Group type: EXPERIMENTAL
Intervention: Riboflavin 400 mg, Magnesium 300 mg, Feverfew 100 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (25 mg riboflavin)
Number of subjects: 120
Study: 11240597

Group type: EXPERIMENTAL
Intervention: IM Fosphenytoin (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IM Saline (up to 19.5 mL or 2 mL)
Number of subjects: 0
Study: 9855446

Group type: EXPERIMENTAL
Intervention: Single dose of influenza vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no vaccination)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Two doses of influenza vaccine (1994-1995 season)
Number of subjects: 28
Study: 7863247

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily a.m.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nizatidine (300 mg twice daily)
Number of subjects: 31
Study: 2491802

Group type: EXPERIMENTAL
Intervention: Heart rate accelerated from low to high at exercise onset
Number of subjects: 5

Group type: COMPARATOR
Intervention: Heart rate held constant at low rate at exercise onset
Number of subjects: 5

Group type: COMPARATOR
Intervention: Heart rate constrained at cessation of exercise
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Abrupt decrease in heart rate at cessation of exercise
Number of subjects: 5
Study: 791382

Group type: EXPERIMENTAL
Intervention: Frontal EMG biofeedback
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo relaxation exercises
Number of subjects: 18
Study: 31734510

Group type: EXPERIMENTAL
Intervention: OM3 (nano-emulsion artificial tear containing CMC, glycerin, flaxseed oil, castor oil, and osmoprotectants)
Number of subjects: 242

Group type: COMPARATOR
Intervention: ROA (artificial tear containing CMC, glycerin, and castor oil, without trehalose and flaxseed oil)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: OM3
Number of subjects: 242

Group type: COMPARATOR
Intervention: ROA
Number of subjects: 242
Study: 31453958

Group type: EXPERIMENTAL
Intervention: CBT-Meno
Number of subjects: 71
Study: 28961465

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Number of subjects: 540

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (both doses)
Number of subjects: 540
Study: 25587172

Group type: EXPERIMENTAL
Intervention: Ambient music during pulmonary rehabilitation session
Number of subjects: 41

Group type: COMPARATOR
Intervention: No ambient music during pulmonary rehabilitation session
Number of subjects: 41
Study: 23485994

Group type: EXPERIMENTAL
Intervention: 3-dimensional RT (3DRT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: 2-dimensional RT (2DRT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: CT-based simulation and planning (3DRT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 253
Study: 21570643

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 62
Study: 17700646

Group type: EXPERIMENTAL
Intervention: E2 (1 mg/day for 1 month, then 2 mg/day for 2 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16484769

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15018290

Group type: EXPERIMENTAL
Intervention: ReliefBand (trained)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Acuband (untrained)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: COMPARATOR
Intervention: ReliefBand (untrained)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Acuband (trained)
Number of subjects: 77
Study: 10697374

Group type: EXPERIMENTAL
Intervention: Amino acid composition (100 mg 3 times a day sublingually)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preductal (20 mg 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 60
Study: 10756785

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: paduden
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: aspirin
Number of subjects: 100
Study: 1527304

Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise test
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low level exercise test
Number of subjects: 202
Study: 4075944

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study: 31291793

Group type: EXPERIMENTAL
Intervention: 600 mg lipoic acid (LA) once daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 28360145

Group type: EXPERIMENTAL
Intervention: Hand nicotine levels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salivary cotinine levels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Association between hand nicotine and cotinine
Number of subjects: 25
Study: 26004515

Group type: EXPERIMENTAL
Intervention: Funding by both panels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Not funded by both panels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall agreement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chance-adjusted agreement
Number of subjects: 60
Study: 25363153

Group type: EXPERIMENTAL
Intervention: Multi-component school-based weight management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study: 22546597

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of interviews
Number of subjects: 1642